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Dois novos biflavonoides 3,5,7,4’-tetraidroxiflavanona-(2→O→4’:3→3’)-2’,4’,6’,4-
tetraidroxidiidrochalcona (1) e 3,5,7,4’-tetraidroxiflavanona-(2→O→7:3→8)-3,4’,5,7-
tetraidroxiflavona (2), denominados amburanina A e amburanina B, respectivamente, foram 
isolados da casca do caule de Amburana cearensis, e as estruturas deles foram elucidadas com 
base em análises espectroscópicas e por comparação com dados da literatura. Os efeitos de 1 e 
2 sobre a resposta pro-inflamatória de neutrófilos humanos foram investigados (0,1; 1; 25; 50 e 
100 µg mL-1). Ambos compostos inibiram em torno de 92% a degranulação de neutrófilos a partir 
da concentração de 25 µg mL-1, e reduziram em até 53% a atividade da mieloperoxidase humana, 
indicando o potencial deles como substâncias anti-inflamatórias.
Two new biflavonoids 3,5,7,4’-tetrahydroxyflavanone-(2→O→4’:3→3’)-2’,4’,6’,4-
tetrahydroxydihydrochalcone (1) and 3,5,7,4’-tetrahydroxyflavanone-(2→O→7:3→8)-3,4’,5,7-
tetrahydroxyflavone (2), named as amburanin A and amburanin B, respectively, were isolated from 
the trunk bark of Amburana cearensis, and their structures elucidated on the basis of spectroscopic 
analysis and by comparison with literature data. The effects of 1 and 2 on the pro-inflammatory 
response of human neutrophils were investigated (0.1; 1; 25; 50 e 100 µg mL-1). At concentration 
higher than 25 µg mL-1, both compounds suppressed nearly 92% of the neutrophil degranulation 
and 53% of myeloperoxidase activity, thus indicating that they are potential anti-inflammatory 
lead compounds.
Keywords: Amburana cearensis, anti-inflammatory, myeloperoxidase, biflavonoids, 
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Introduction
Amburana cearensis A. C. Smith (syn.: Torresea 
cearensis Fr. All.), commonly known as “cumaru” or 
“imburana-de-cheiro”, is a native tree from northeastern 
Brazil. Popularly, the trunk bark and seeds are utilized 
either as a household medicine (“lambedô”) or as 
a syrup commercially available to treat respiratory 
conditions (asthma and bronchitis).1 Previously, the 
aqueous alcohol extract of the trunk bark showed 
bronchodilatory, anti-inflammatory and analgesic 
properties.2 One of its constituents, amburoside A 
[(4-O-β-D-glucopyranosylbenzyl) protocatechuate], 
showed neuroprotective and hepatoprotective effects,3,4 
while a second compound, isokaempferide, exhibited 
bronchodilator and antiproliferative activities.5,6 Both 
amburoside A and isokaempferide displayed anti-
inflammatory activity.7 Coumarin, the most abundant 
component, also exhibited bronchodilator, antimalarial, 
and antileishmanial activities.2,8
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P r ev i o u s  p h y t o c h e m i c a l  s t u d i e s  o f  t h e 
trunk bark of A. cearensis revealed several other 
known  pheno l i c  compounds :  amburos ide  B 
[ (4-O -β -D-glucopyranosylbenzyl)  vani l la te] , 8 
vanillic acid (4-hydroxy-3-methoxybenzoic acid), 
protocatechuic acid (3,4-dihydroxybenzoic acid), 
afrormosin (7-hydroxy-4’,6-dimethoxyisoflavone), 
kaempferol (4’,5,7-trihydroxyflavonol), quercetin 
(3’,4’,5,7-tetrahydroxyflavonol) and 4’-O-methylfisetin 
(3’,7-dihydroxy-4’-methoxyflavonol).9 Later on, novel 
compounds such as glucosylprotocatechuate derivatives 
(amburosides C-H) and 6-coumaryl protocatechuate were 
reported from either the trunk bark or seeds of A. cearensis, 
besides 6-hydroxycoumarin and formononetin.10 
Furthermore, 3’,4’-dimethoxy-1’-(7-methoxy-4-oxo-4H-
chromen-3-yl)benzo-2’,5’-quinone along with five known 
flavonoids were isolated from resin of A. cearensis.11 
Phytochemical analyses associated with pharmacological 
studies revealed that cultivated young plants of A. cearensis 
exhibited similar chemical and pharmacological profiles 
as the wild plant.12,13 Recently, we have also studied the 
physicochemical characteristics of the spray-dried ethanol 
extract for obtaining A. cearensis powders with better 
pharmacological and technological properties.14
This report will discuss the isolation and structural 
elucidation of two daphnodorin-type biflavonoids from 
A. cearensis trunk bark (Figure 1), as well as their 
in vitro effect on human neutrophil degranulation and 
myeloperoxidase (MPO) activity.
Experimental
General experimental procedure
Melting points (uncorr.) were determined with a 
Mettler Toledo FP82HT apparatus (Columbus, OH, USA), 
with a heating rate of 2 °C min-1. Optical rotations were 
measured on a Perkin-Elmer 341 polarimeter (at 589 nm) 
in MeOH at 20 °C. Electronic circular dichroism (ECD) 
spectra were recorded in high purity MeOH on a JASCO 
J-815 CD spectrometer (Easton, MD, USA) at 25 °C using 
a 1 cm path length quartz cuvette. ECD spectra for both 
compounds were obtained at concentrations of 0.10, 0.08, 
0.06, 0.04, and 0.02 mmol mL-1 in order to determine the 
concentration which produced the highest quality data. UV 
spectra were obtained on a Varian Cary 50 Conc UV-Visible 
spectrophotometer (Mulgrave, Australia). Infrared (IR) 
spectra were recorded with a Perkin-Elmer FT-IR 1000 
spectrometer (Waltham, MA, USA), using KBr pellets. 
Nuclear magnetic resonance (NMR) experiments were 
performed on a Bruker DRX-500 spectrometer (Bruker 
Biospin, Rheinstetten, Germany) at room temperature, 
using dry DMSO-d6 as solvent (Cambridge Isotope 
Laboratories), and were internally referenced to residual 
undeuterated solvent signals (dH 2.50 and dC 39.51 ppm). 
High resolution mass spectra (HR-MS) were recorded 
on a Q-TOF Xevo mass spectrometer (Waters, Milford, 
USA), utilizing an electrospray ionization (ESI) source 
as ionization method. Column chromatography was run 
on silica gel 60 (70-230 mesh, VETEC) and Sephadex 
LH-20 (Amersham Pharmacia Biotech). Thin layer 
chromatography (TLC) was performed on precoated 
silica gel polyester sheets (Merck) and monitored by UV 
detection and vanillin-perchloric acid reagent detection. 
High performance liquid chromatography (HPLC) 
purification was performed on a Waters 1525 (Milford, 
MA, USA) chromatograph, equipped with a binary pump, 
Rheodyne injector (200 µL loop), and photodiode-array 
detector (Waters-2996 PDA), using a Waters X-Terra RP-18 
column (250 × 4.6 mm, 5 µm) at 35 ºC in a thermostatic 
oven. HPLC MeOH was purchased from Tedia Co, 
and HPLC grade water (18 mΩ) obtained by a Milli-Q 
purification system (Millipore, Bedford, MA, USA).
Plant material
Trunk bark of A. cearensis was collected in the 
Quixeramobim region, Ceará State, Northeastern Brazil, in 
September 2002. Voucher specimens (# 837 and 847) were 
deposited at the Prisco Bezerra Herbarium, and identified 
by Dr. Afrânio G. Fernandes, a botanist at the Departamento 
de Biologia, Universidade Federal do Ceará.
Extraction and isolation
A. cearensis was submitted to a similar procedure 
as that previously described by Canuto et al..10 Briefly, 
powdered dried trunk bark (4.0 kg) was extracted with 
EtOH in a Soxhlet apparatus, yielding 192.5 g (4.8% m/m) 
Figure 1. Structures of amburanins A (1) and B (2). 
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of a viscous brown extract, which was suspended in H2O 
(350 mL) and partitioned with EtOAc (150 mL, 3×). 
Afterwards, the fractions were evaporated and lyophilized. 
The EtOAc fraction (82.6 g) was dissolved in MeOH 
(200 mL) and defatted with hexane (100 mL, 3×) to provide 
64.5 and 16.6 g of the MeOH (ACM, brown solid) and 
hexane (ACH, green solid) residues, respectively. The 
latter fraction was discarded, whereas ACM was adsorbed 
onto 65 g of silica gel and eluted with CHCl3 (0.5 L); 
CHCl3/EtOAc 1:1 (3.5 L); EtOAc (2.0 L), and finally 
MeOH (0.5 L) to afford 2.1, 22.7, 25.3, and 12.3 g fractions, 
respectively. The CHCl3-EtOAc (1:1) fraction was adsorbed 
onto 160.2 g of silica gel in a glass column (500 mL) and 
chromatographed, collecting fractions of 75 mL with the 
following eluents: CHCl3 (F1-6), CHCl3-EtOAc (9:1) 
(F7-18), CHCl3-EtOAc (8:2) (F19-25), CHCl3-EtOAc (6:4) 
(F26-29), CHCl3-EtOAc (1:1) (F30-31), EtOAc (F32), and 
MeOH (F33). Fractions F1-2, F3-7, F8-15, F16-19, F20-23, 
and F24-31 were each pooled together after TLC analysis. 
F24-31 (4.0 g) was subjected to Sephadex LH-20 (60 g) 
column chromatography with MeOH as the eluent, resulting 
in 34 fractions of 75 mL each. The fractions were analyzed 
by TLC and pooled to yield F’1, F’2-8, F’9-18, F’19-33, 
and F’34. F’34 was identified as quercetin (40 mg, dark 
yellow solid). F’2-8 was re-subjected to Sephadex LH-20 
column chromatography under the same conditions as 
used previously, resulting in the isolation of protocatechuic 
acid (F’’4-6: 186 mg, yellow crystals), amburoside A 
(F’’8-13: 954 mg, pink solid) and vanillic acid (F’’14-15: 
47 mg, yellowish crystals). F’9-18 (1.5 g) was subjected 
to successive Sephadex LH-20 column chromatography, 
eluted with MeOH to yield compound 1 (61 mg, yellow 
powder). F’19-33 was also chromatographed on Sephadex 
LH-20 (8.0 g) with MeOH, yielding 15 fractions of 
3 mL each. Fractions F’’5 to F’’12 were pooled. F’’5-12 
(162 mg) was purified by HPLC/PDA (loop = 200 µL) on a 
250 × 10 mm i.d. X-Terra RP-18 column, using H2O-MeOH 
as the mobile phase at a flow rate of 4.5 mL min-1. The 
elution gradient varied from 60 to 75% MeOH over 10 min 
total run time. The chromatogram was observed at 284 nm 
and showed one of the peaks corresponding to compound 2 
(tR = 8.8 min, 53 mg, yellow powder). 
Amburanin A (1)
Yellow powder (MeOH); m.p. > 300 °C; [a]D20 −15.9 
(c 0.24, MeOH); UV (MeOH) λmax/nm (log ε) 291 (4.96), 
230 (5.18), 208 (5.26); IR (KBr) νmax/cm-1 3335 (O–H), 
1641 (>C=O), 1512, 1440, 1252, 1171, 955. For 1H and 
13C NMR spectroscopic data, see Table 1. HRESIMS 
m/z 581.1060 [M+Na]+ (calcd. for C30H22O11Na, 581.1063); 
m/z 557.1066 [M–H]– (calcd. for C30H21O11, 557.1084).
Amburanin B (2)
Yellow powder (MeOH); m.p. > 300 °C, [a]D20 −12.4 
(c 0.21, MeOH); UV (MeOH) λmax/nm (log ε) 285 (4.73), 
227 (4.98), 208 (5.06); IR (KBr) νmax/cm-1 3433 (O–H), 
1640 (>C=O), 1517, 1473, 1329, 1258, 1168. For 1H and 
13C NMR spectroscopic data, see Table 1. HRESIMS 
m/z 593.0679 [M+Na]+ (calcd. for C30H18O12Na, 593.0696); 
m/z 571.0853 [M+H]+ (calcd. for C30H19O12, 571.0877).
Human neutrophil degranulation assay 
Human neutrophils from peripheral blood of healthy 
volunteers were isolated using the method described by 
Lucisano and Mantovani.15 The cell preparations presented 
90% neutrophils with 97.7 ± 0.94% viability, determined by 
the Trypan blue test. According to the procedure reported 
by Boyum,16 aliquots of 5 × 106 cells mL-1 were suspended 
in buffered Hank’s balanced salt solution (HBSS) and 
then incubated at 37 °C with compounds 1 and 2 (0.1, 1, 
25, 50, and 100 mg mL-1) or indomethacin (36 mg mL-1, 
standard compound) for 15 min at 37 ºC. The cells were 
then stimulated with phorbol-myristate-acetate (PMA, 
0.1 mg mL-1) for 15 min at 37 ºC. The resulting suspension 
was centrifuged for 10 min at 2000 × g at 4 ºC and aliquots 
(50 µL) of the supernatants were then added to phosphate-
buffered saline (100 µL), sodium phosphate buffer 
(6.1 mmol L-1 Na2HPO4 and 74 mmol L-1 Na2HPO4.2H2O, 
50 µL, pH 5.4) and H2O2 (0.012%). After 5 min at 37 ºC, 
3,3’,5,5’-tetramethylbenzidine (TMB, 1.5 mmol L-1, 20 µL) 
was added and the reaction was stopped by 30 µL of NaOAc 
(1.5 mol L-1, pH 3.0). Absorbance was recorded at 620 nm.
Myeloperoxidase activity assay
The aforementioned method16 was modified to evaluate 
the effect of the bioflavonoids on MPO activity. Human 
neutrophils were stimulated with PMA, and the MPO-rich 
supernatant was separated by centrifugation. Aliquots of 
the supernatant were incubated at 37 °C with compounds 1 
and 2 (25, 50, and 100 µg mL-1), DMSO (1% v/v, vehicle) 
or HBSS (untreated cells) for 15 min, before determining 
MPO activity.
Cytotoxic assay
Human neutrophils (5 × 106 cells mL-1) were incubated at 
37 °C with the compounds 1 and 2 (25, 50 and 100 µg mL-1), 
DMSO (1% v/v, control/vehicle), HBSS (untreated cells) or 
Triton X-100 (0.2% v/v, standard compound) for 30 min at 
37 °C, and before adding 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT) to the medium. 
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After 3 h under a 5% CO2 atmosphere, the cells were 
washed with PBS, and the formazan product was dissolved 
in 100 µL of DMSO. The absorbance was recorded at 
550 nm;17 its values decreased as a function of cell death.
Results and Discussion
The ethanol extract of A. cearensis trunk bark was 
subjected to liquid-liquid partitioning (EtOAc/H2O) to 
yield an EtOAc phase that was further separated by either 
silica gel or Sephadex LH-20 column chromatography. 
Subsequent HPLC and spectroscopic analysis of 
purified compounds led to the isolation and structural 
characterization of biflavonoids 1 and 2, along with known 
compounds vanillic acid, protocatechuic acid, quercetin 
and amburoside A.9
Compound 1, a yellow powder, showed quasi-molecular 
ions at m/z 581.1060 [M+Na]+ (calcd. for C30H22O11Na, 
581.1063) and 557.1066 [M-H]– (calcd. for C30H21O11, 
557.1084) in its HRESIMS spectrum. A broad and intense 
IR absorption band centered at 3335 cm-1 confirmed the 
presence of hydroxy groups, while an intense band with a 
shoulder at 1641 cm-1 suggested the presence of conjugated 
carbonyl functionalities. Additional IR absorption bands at 
1252 and 1171 cm-1 were attributed to phenolic and tertiary 
alcohol C-O stretching frequencies, respectively. 
The 1H NMR spectrum for compound 1 in dry DMSO-d6 
displayed two methylene proton triplets at dH 2.87 and 3.29 
(t, 2H, J 7.7 Hz, H-IIβ and H-IIa), and two m-coupled 
doublets at dH 5.86 and 5.95 (d, 1H, J 2.0 Hz, H-I8 and 
H-I6), the latter characteristic of the I-A-ring aromatic 
protons. Five sharp singlets at dΗ 6.51, 9.17, 9.77, 11.70 
and 13.17 (s, 1H), in addition to a broad singlet at dH 11.02 
(s, 2H) characterized seven hydroxy groups. Four pairs of 
two-proton doublets at dH 6.62, 7.02 (d, 2H, J 8.4 Hz, H-II3, 
5 and H-II2, 6), 6.72 and 7.25 (d, 2H, J 8.7 Hz, H-I3’, 5’ 
and H-I2’, 6’) were characteristic of two para-disubstituted 
aromatic rings, while a singlet at dH 5.96 (s, 1H, H-II5’) was 
associated with the single hydrogen on the pentasubstituted 
benzene ring. A gradient-selective correlation spectroscopy 
(gs-COSY) spectrum showed, as expected, scalar coupling 
between the two aliphatic methylenes and hydrogen at 
dH 6.62 (d, 2H, J 8.4 Hz, H-II3, 5) and the hydrogens at 
dH 7.02 (d, 2H, J 8.4 Hz, H-II2, 6), as well as between the 
hydrogens at dH 6.72 (d, 2H, J 8.7 Hz, H-I3’, 5’) and those 
at dH 7.25 (d, 2H, J 8.7 Hz, H-I2’, 6’). 
The 13C NMR composite pulse decoupling (CPD) 
spectrum showed 26 resonances, four of which had 
intensities indicative of the two sets of carbons on 
para-disubstituted aromatic rings. The distortionless 
enhancement by polarization transfer (DEPT) 135 spectrum 
confirmed the presence of two saturated methylene carbons 
at dC 30.3 (C-IIβ) and 45.3 (C-IIa), the methine carbons of 
the p-disubstituted aromatic rings at dC 115.6 (C-I3’, 5’), 
115.9 (C-II3, 5), 129.3 (C-I2’, 6’) and 130.0 (CII-2, 6), and 
three methine sp2 carbons at d 95.5 (C-I8), 97.5 (C-I6) and 
98.5 (C-II5’).
The 13C NMR data (Table 1) showed the presence of 
two carbonyl carbons; one at dC 203.7 (C-IIβ’), related 
to a dihydrochalcone as suggested by the presence of 
the two methylene carbons, and one at dC 192.2 (C-I4), 
characteristic of a dihydroflavonol moiety. The presence 
of eight oxygenated aromatic carbons was inferred from 
the carbon resonances at dC 156.4 (C-II4), 159.5 (C-I4’), 
161.3 (C-I9), 162.2 (C-II6’), 163.5 (C-I5), 164.0 (C-II2’), 
166.7 (C-II4’) and 167.7 (C-I7). A further conclusion 
from the chemical shifts of these carbons is that there 
were not oxygenated ortho-carbons, as such species would 
lead to more shielded chemical shifts (144 ≤ dC ≤ 148).18 
This suggested that the A-ring oxygenation pattern 
followed the common phloroglucinol A-ring theme for 
flavonoids.18 A saturated quaternary carbon bearing an 
oxygen atom at dC 80.5 (C-I3) was readily characterized, 
while the dioxygenated carbon at d 118.6 (C-I2) was 
identified by comparison with the chemical shifts of 
dihydroflavonol moieties from the daphnodorins isolated 
from Daphne odora Thunb.19
The heteronuclear single quantum coherence (HMQC) 
spectrum permitted the correlation of all protonated carbons 
(Table 1). The heteronuclear multiple-bond correlation 
(HMBC) data were of crucial importance for confirming 
structural assignments and correctly positioning the 
hydroxy groups and all non-protonated carbons. From 
Table 1 it is evident that the assignments of C-6 and C-8 
could mistakenly be interchanged, as C-6 is slightly more 
deshielded than C-8.18 Unambiguous assignment was, 
however, possible due to several key HMBC correlations. 
The hydrogen at dH 5.86 (H-I8) showed two- and three-
bond correlations to the carbons at dC 99.4 (C-I10) and 
161.3 (C-I9), respectively, while the one at dH 5.95 (H-I6) 
exhibited correlations to the carbons at dC 163.5 (C-I5) 
and 95.5 (C-I8). The doublet at dH 7.25 (H-I2’, 6’) showed 
a three bond correlation with the dioxygenated carbon 
at dC 118.6 (C-I2), whereas the one at dH 7.02 (H-II2, 
6) correlated to the monoxygenated carbon at dC 156.4 
(C-II4). The respective correlations involving the methylene 
hydrogens at dH 3.29 (H-IIa) and 2.87 (H-IIβ) with the 
methylene carbon at dC 30.3 (C-IIβ) and the carbonyl 
carbon at dC 203.7 (C-IIb’) ratified the presence of the 
dihydrochalcone moiety. The hydrogen at dH 5.96 (H-II5’) 
additionally presented “W”-coupling (4J) with the CII-β’ 
carbonyl carbon and with the carbons at dC 108.4 (C-II3’) 
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and 166.7 (C-II4’). The linkage between the two flavonoid 
moieties via a dihydrofuran ring was confirmed by the 
coupling of the hydroxy hydrogen at dH 6.51 (HO–C-I3) 
with the carbons at dC 118.6 (C-I2) and 108.4 (C-II3’). 
Long-range correlations for the hydroxy hydrogens further 
corroborated the suggested structure. The hydrogen-bonded 
hydroxy group at dH 13.17 correlated to carbon resonances 
at dC 162.2 (C-II6’, 2J), 101.9 (C-II1’, 3J) and 98.5 (C-II5’, 
3J), while the hydroxy proton at dH 11.70 (H-II2’) correlated 
to d 164.0 (C-II2’). Figure 2 shows additional important 
C-H correlations observed in the HMBC spectrum.
Thus ,  the  s t ruc ture  of  1  was  ass igned as 
3,5,7,4’-tetrahydroxyflavanone-(2→O→4’:3→3’)-
2’,4’,6’,4-tetrahydroxydihydrochalcone, an adduct of the 
flavonol kaempferol and the dihydrochalcone phloretin, 
and named amburanin A. Comparison of the 13C NMR 
chemical shifts reported for these two monomers with those 
of compound 1, shows agreement, taking into account the 
Table 1. 1H and 13C NMR data (d in ppm, J in Hz) of compounds 1 and 2 (500/125 MHz, respectively, DMSO-d6)a
Amburanin A (1) Amburanin B (2)
C# dC dH C# dC dH 
I-2 118.6 – I-2 118.7 –
I-3 80.5 – I-3 80.8 –
I-4 192.2 – I-4 191.8 –
I-5 163.5 – I-5 164.3 –
I-6 97.5 5.95 ( d, 1H, J 2.0) I-6 97.8 5.95 (d, 1H, J 2.0)
I-7 167.7 – I-7 168.4 –
I-8 95.5 5.86 (d, 1H, J 2.0) I-8 96.0 5.92 (d, 1H, J 2.0)
I-9 161.3 – I-9 161.3 –
I-10 99.4 – I-10 99.6 –
I-1’ 124.5 – I-1’ 124.5 –
I-2’, 6’ 129.3 7.25 (d, 2H, J 8.7) I-2’, 6’ 129.2 7.28 (d, 2H, J 8.7)
I-3’, 5’ 115.6 6.72 (d, 2H, J 8.7) I-3’, 5’ 115.7 6.79 (d, 2H, J 8.7)
I-4’ 159.5 – I-4’ 159.6 –
II-1’ 101.9 – II-2 148.3 –
II-2’ 164.0 – II-3 136.9 –
II-3’ 108.4 – II-4 177.1 –
II-4’ 166.7 – II-5 164.7 –
II-5’ 98.5 5.96 (s, 1H) II-6 95.6 6.71 (s, 1H)
II-6’ 162.2 – II-7 165.7 –
β' 203.7 – II-8 106.9 –
a 45.3 3.29 (t, 2H, J 7.7) II-9 152.1 –
β 30.3 2.87 (t, 2H, J 7.7) II-10 106.1 –
II-1 131.8 – II-1’ 122.2 –
II-2, 6 130.0 7.02 (d, 2H, J 8.4) II-2’, 6’ 131.0 8.16 (d, 2H, J 8.7)
II-3, 5 115.9 6.62 (d, 2H, J 8.4) II-3’, 5’ 116.3 6.94 (d, 2H, J 8.7)
II-4 156.4 – II-4’ 160.4 –
OH (I-3) – 6.51 OH (I-3) – 6.96
OH (I-5) – 11.02 OH (I-5) – 11.80
OH (I-7) – 11.02 OH (I-7) – 11.02
OH (II-2’) – 11.70 OH (I-4’) – 9.80
OH (II-6’) – 13.17 OH (II-3) – 9.66
OH (I-4’) – 9.77 OH (II-5) – 13.30
OH (II-4) – 9.17 OH (II-4’) – 10.20
aAssignments were confirmed by 2D 1H–1H (COSY) and 2D 1H–13C (HMQC, HMBC) experiments.
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empirical influence of the substitution effect.18 This effect 
is particularly noticeable for C-II3’ as it is deshielded by 
12.7 ppm due to the “ipso” effect of C-I3, and for C-I3 as 
it is deshielded by 6.8 ppm due to the a-effect of C-II3’.18 
Although compound 1 possessed a negative specific 
rotation, ([a]D20 −15.9, c 0.24, MeOH), the experimental 
ECD spectrum (not shown) lacked distinct Cotton effects 
(CEs) at all concentrations examined, indicating a lack of 
enantiomeric purity. 
Compound 2 was obtained as a yellow powder, with a 
molecular formula of C30H18O12 as revealed by a HREIMS 
quasi-molecular ions at m/z 593.0679 [M+Na]+ (calcd. for 
C30H18O12Na, 593.0696); m/z 571.0853 [M+H]+ (calcd. for 
C30H19O12, 571.0877). Its FT-IR spectrum exhibited a broad 
absorption band centered at 3433 cm-1, characteristic of 
hydroxy groups, and an absorption band with a shoulder 
at 1640 cm-1 characteristic of C=O stretching. Absorption 
bands at 1258 cm-1 and 1168 cm-1 were characteristic of 
phenolic and tertiary alcohol C–O stretching frequencies, 
similar to those observed for 1.
The 1H NMR spectrum displayed two m-coupled one-
proton doublets at dH 5.92 and 5.95 (d, 1H, J 2.0 Hz, H-I8 
and H-I6), a one-proton singlet at dH 6.71 (s, 1H, H-II6) and 
two pairs of o-coupled two-proton doublets at dH 6.79 (d, 
2H, J 8.7 Hz, H-I3’,5’), 6.94 (d, 2H, J 8.7 Hz, H-II3’,5’), 
7.28 (d, 2H, J 8.7 Hz, H-I2’,6’) and 8.16 (d, 2H, J 8.7 Hz, 
H-II2’,6’). The o-coupled two-proton doublets showed the 
same relative coupling patterns (dH 6.79 with 7.28 and dH 
6.94 with 8.16) as observed for compound 1.
The 13C NMR (CPD) spectrum of 2 was similar to that 
of compound 1 and showed 26 resonances between dC 80 
and 192, two with prominent intensities. From Table 1, it 
is evident that the dihydroflavonol moiety is the same for 
both compounds. The chemical shift of the second carbonyl 
absorption (dC 177.1, C-II4), however, indicated that the 
second C6–C3–C6 unit was a flavonol moiety instead of a 
dihydrochalcone. This was supported by the lack of the 
two saturated methylene carbons seen in compound 1. 
Two sp2 carbons at d 136.9 (C-II3) and 148.3 (C-II2) were 
instead present, further supporting the assignment of a 
flavonol moiety. 
The HMQC and HMBC experiments corroborated 
the suggested structure. The most important C–H long-
range correlations in the HMBC spectrum are depicted in 
Figure 3. Thus, compound 2 was structurally characterized 
as 3,5,7,4’-tetrahydroxyflavanone-(2→O→7:3→8)-
3,4’,5,7-tetrahydroxyflavone, an adduct of two kaempferol 
molecules, and named amburanin B. Since the ring closure 
of the flavonol moiety could have occurred via either the 
C-II9 or C-II5 hydroxy group, the HMBC experiment was 
again of crucial importance. As depicted in Figure 3, the 
hydrogen-bonded hydroxy proton at d
 
13.3 (HO–C-II5) 
correlated to the carbons at dC 95.6 (C-II6, 3J), 106.1 (C-
II10, 3J) and 164.7 (C-II5, 2J), unequivocally confirming 
structure 2.
Although compound 2 possessed a low magnitude 
negative specific rotation of [a]D20 −12.4 (c 0.21, MeOH), 
the experimental ECD spectrum (Figure S17 in the 
Supplementary Information section) contained distinct 
CEs which appeared to correspond to the multiple UV 
maxima for the compound. Attempts to interpret these CEs 
based on the precedent of the daphnodorins,19,20 however, 
revealed a series of significant differences between ECD 
data for the daphnodorins with their flavan and flavan-
3-ol constituents units, and compound 2. However, the 
negative CE at ca. 320 nm presumably indicates (2S, 
3S) absolute configuration for this compound based on 
the ECD data of daphnodorins F and H with similar 
configuration at C-2 and C-3. The low magnitude of the 
specific rotation of compound 2 presumably reflects a 
low degree of enantiomeric purity when compared to the 
reported values for daphnodorins F and H (–120.0 and 
–170.4, respectively).16,19
Figure 2. HMBC correlations (H→ C) observed for compound 1.
Figure 3. HMBC correlations (H→ C) observed for compound 2.
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Although the two new amburanins A and B (1 and 2) are 
here described for the first time, analogous dihydrofuran-
type biflavonoids, the daphnodorins, have been reported 
from Glycyrrhiza glabra L. (Fabaceae)21 and several 
species of the genus Daphne (Thymelaeaceae) including 
D. odora,18,20 D. acutiloba Rehd.,22 D. genkwa Sieb. et 
Zucc.,23 D. giraldii Nitsche24 and D. tangutica Maxim.25 
These compounds have shown pharmacological activities 
including in vitro and in vivo cytotoxicity,23,25-27 antifungal 
and anti-HIV activities,28 and inhibitory effects on human 
chymase and 12-lipoxygenase.27-30
In previous studies,2,4,7,13,31 it has been shown that 
hydroalcohol extract, coumarin, isokaempferide, 
amburoside A, vanillic acid and afrormosin from 
A. cearensis display various pharmacological properties. 
These molecules showed anti-inflammatory activity in 
rodents by inhibiting paw edema and the accumulation of 
inflammatory cells into the peritoneal cavity of mice. In 
addition, isokaempferide and amburoside A were able to 
inhibit human neutrophil degranulation, myeloperoxidase 
activity and the secretion of TNF-a by human neutrophils, 
showing no cytotoxicity at the concentrations investigated. 
Other studies have shown the anti-inflammatory properties 
of vanillic and protocatechuic acids.31-33 Additional 
investigations into the possible anti-inflammatory activities 
of amburanins A and B were therefore deemed worthwhile, 
as these compounds could contribute to the biological 
activities of A. cearensis.
The recruitment and activation of polymorphonuclear 
leukocytes (PMNs) is considered one of the main defense 
mechanisms of innate immunity. Chemical mediators 
subsequently released by activated cells play an important 
role in the pathophysiology of several inflammatory 
diseases, such as rheumatoid arthritis, pulmonary 
emphysema and asthma.34-36 As part of the first line of 
host defense, PMNs possess bactericidal activities and 
are involved in pathogen adherence, chemotaxis towards 
infected cells, and phagocytosis of pathogens and damaged 
cells.37 Activation of various PMNs during inflammatory 
processes results in the release of complement components, 
reactive oxygen species and lysosomal enzymes, including 
MPO. MPO levels can therefore serve as an index of 
neutrophil recruitment and activation and also display 
traditional cytokine-like properties that can serve 
to modulate the activation state of leukocytes in the 
inflammatory process.38-40 In addition, MPO has direct 
effects on endothelial cells since its internalization by 
these cells is followed by the intracellular production of 
oxidants.41
The possible effects of biflavonoids 1 and 2 on the 
neutrophil degranulation were assessed by measuring 
MPO release by PMA-stimulated cells. Exposure of 
neutrophils to compounds 1 and 2 (0.1-100 µg mL-1) 
caused an inhibition of MPO release (Figure 4) that was 
comparable to the effects of indomethacin (36 µg mL-1), a 
non-selective cyclooxygenase inhibitor used as reference 
compound. At concentrations higher than 10 µg mL-1, 
biflavonoids 1 and 2 inhibited MPO activity by 45.5 and 
52.7%, respectively; at 36 µg mL-1, indomethacin inhibited 
MPO activity by 45% (Figure 5). Compared with the 
control group (115.2 ± 3.8%), 1 and 2 did not interfere 
significantly in the cell viability at concentrations ranging 
from 10 to 100 µg mL-1; the reference compound Triton 
X-100 reduced the cell viability to 12.1% (Figure 6). 
Figure 4. Effects of biflavonoids 1 and 2 on the human neutrophil 
degranulation assayed using release MPO as marker. Freshly isolated cells 
(5 × 106) were preincubated with the indicated concentration of 1 or 2 prior 
to the addition of PMA (0.1 mg mL-1). Data are expressed as percentage 
of inhibition of MPO release by the tested compounds. Numbers represent 
mean ± standard error of the mean (SEM).
Figure 5. Effects of biflavonoids 1 and 2 on the activity of human 
neutrophil myeloperoxidase (MPO). The MPO-rich supernatant obtained 
from PMA-stimulated neutrophils was incubated with compound 1 or 
2 at the concentrations indicated in the graph. Data are expressed as 
percentages of inhibition of MPO activity by the tested compounds. 
Numbers represent mean ± SEM.
Figure 6. Evaluation of biflavonoids 1 and 2 toxicity towards human 
neutrophils. Data from two to eight samples. *p < 0.05 (ANOVA and 
Tukey’s post hoc test).
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These results provide evidence that the biflavonoids 
amburanins A and B have anti-inflammatory potential 
through the modulation of human neutrophil degranulation, 
but this effect seems is related at least in part to a direct 
effect of the biflavonoids on the MPO activity. Furthermore, 
the anti-inflammatory activity of these biflavonoids 
seems not to be related to a cytotoxic effect, since these 
compounds did not affect the neutrophil viability, as 
assayed by the MTT assay. In this context, because 
neutrophils play important roles in the pathophysiology 
of several inflammatory diseases and the MPO activity 
correlates well with leukocytes infiltration in inflamed 
regions,42 it is likely that pharmacological activities of 
amburanins A and B reported here have beneficial effects 
in the treatment of inflammatory diseases.
Conclusions
The chemical investigation of Amburana cearensis trunk 
bark permitted the isolation of two unusual biflavonoids, 
amburanins A and B (compounds 1 and 2). These compounds 
displayed inhibition of human neutrophil pro-inflammatory 
responses, such as degranulation and MPO activity, 
suggesting potential anti-inflammatory effects similar to 
those of co-occurring amburoside A, isokaempferide and 
afrormosin.7,31 These findings corroborate the folk usage of 
this plant, justifying its pharmacological potential for the 
treatment of inflammatory diseases such as asthma. 
Supplementary Information 
Supplementary data of the compounds 1 and 2 (NMR, 
IR and HR-MS spectra, Figures S1-S17) are available free 
of charge at http://jbcs.sbq.org.br as PDF file. 
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